PerkinElmer, Inc., (Waltham, Massachusetts, USA) has announced that it is to establish a personalized health innovation centre of excellence.
PerkinElmer, Inc., (Waltham, Massachusetts, USA) has announced that it is to establish a personalized health innovation centre of excellence. The centre will focus on accelerating scientific innovation to help researchers who are working to eradicate disease and extend the quality and longevity of life.
The centre will bring together leaders from PerkinElmer's chemistry, biochemistry, cell biology, molecular biology and reagent development R&D teams. They will focus on the development of key enabling applications solutions in genomics, imaging, biomarkers, biotherapeutics, targeted small molecule development and cell-based assay solutions. The centre will also showcase a complete solutions-based demonstration laboratory for customers and collaborators.
The centre will be located at the company’s facility in Hopkinton, Massachusetts, USA, and is hoped to be fully operational by late 2012.
Kevin Hrusovsky, President, Life Sciences & Technology, PerkinElmer, said, “We are delighted to establish our new centre of excellence, which will serve as an exciting example of PerkinElmer’s commitment to, and culture of, innovation. The expertise promoted by the centre will help bring novel and disruptive solutions to our customers, aiding their research in next generation treatments, early detection and disease prevention.”
For more information please visit ref="http://www.perkinelmer.com">www.perkinelmer.com
Assessing Safety of Medications During Pregnancy and Breastfeeding with LC–MS/MS
Published: April 8th 2025 | Updated: April 8th 2025Researchers conducted a study on medications used in psychiatry and neurology during the perinatal period, assessing how antiepileptic drugs (AEDs) affect placental functions, including transport mechanisms, nutrient transport, and trophoblast differentiation. Several quantitative methods, such as those for antianxiety and hypnotic drugs, were established to evaluate the safety of pharmacotherapy during breastfeeding using liquid chromatography-tandem mass spectrometry (LC–MS/MS).